KRAS and Miyoshi myopathy: To investigate if the occurrence of KRAS-mutations has a prognostic role for newly diagnosed MM patients treated with current treatment regimens including novel agents, and whether the exon-4 mutations may play a functional role in MM pathogenesis, we performed deep-sequencing of the coding regions of KRAS in samples from 80 MM patients at diagnosis, who were then uniformly treated with bortezomib and high-dose chemotherapy.